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See related article on page 569.doi:10.1016/j.jtcvs.2004.09.017During the more than 3 decades that have transpired since theearliest reports of “corrective surgery” for tricuspid atresia byFontan and Baudet1 and Kreutzer and colleagues,2 the generalprinciples of their operations have increasingly been applied to awide spectrum of cardiovascular anomalies characterized by afunctional single ventricle or nonseptatable heart. These surgical
reconstructions, culminating in diversion of systemic venous return directly to the
pulmonary arteries, are generally referred to as modified Fontan procedures. The
earliest of these operations were technically complicated affairs with intentional
implantation of valves in the venous pathways and frequent use of conduits made
from various prosthetic and biologic materials. Over 30 years, the operations have
evolved in a direction characterized by technical simplification of the pathways and
procedures. Currently, modified Fontan procedures are really total cavopulmonary
connections. The use of prosthetic materials has been minimized but not eliminated.
Valves are no longer integrated into the venous pathways. The completed Fontan
procedure is most often, although not always, achieved in 2 steps with a hemi-
Fontan or superior cavopulmonary anastomosis, which is ultimately followed by a
completion Fontan procedure that directs inferior caval flow to the pulmonary
arteries, either entirely by extracardiac connections or by an intraatrial tunnel. The
trend in operative mortality for modified Fontan procedures has been one of steady
improvement from mortality rates of 25% to 30% in the earliest series to less than
5% in contemporary reports. Despite this record of progress, some factors contrib-
uting to morbidity and mortality persist. One of the major factors contributing to
morbidity and failure of the Fontan circulation is the group of events referred to as
thromboembolic complications. This vexing problem, and in particular the question
of the potential benefit of prophylactic anticoagulant therapy in patients who
undergo the Fontan operation, is the subject of ongoing controversy that challenges
cardiologists, cardiothoracic surgeons, critical care physicians, and hematologists
caring for this patient population. “Prophylaxis of Thromboembolic Complications
After the Fontan Operation (Total Cavopulmonary Anastomosis)” is the title and
subject of a retrospective review by Kaulitz and colleagues3 in this issue of the
Journal. The authors review their experience with 142 survivors of modified Fontan
operations, with follow-up ranging from 12 to 177 months. All operations were
performed by a single surgeon, and the initial postoperative strategy for anticoag-
ulation was based primarily on the surgical method and influenced by preoperative
parameters and early postoperative functional status. Thus, 85 patients with partial
prosthetic venous pathway (with or without fenestration) received acetylsalicylic
acid 3 to 5 mg/kg per day. Twenty-nine other patients with partial prosthetic
pathway “and uncomplicated early postoperative period” and 16 patients with
autologous tissue venous pathway received no anticoagulation. Six patients received
warfarin sodium (Coumadin) as initial therapy “because of borderline perioperative
hemodynamic parameters or related to surgical technique.” The original antithrom-
botic strategy was modified during follow-up when thromboembolic complications
occurred or atrial arrhythmias, protein-losing enteropathy, polycythemia, or ven-
tricular dysfunction associated with systemic venous slow blood flow phenomenon
on echocardiogram developed. The authors suggested that these latter phenomena
constituted circumstances associated with an increased risk of thromboembolism,





Laccording to their interpretation of previously published
reports. Thus, in addition to 6 patients who received war-
farin as primary therapy, 22 additional patients “crossed
over” to warfarin on the basis of the occurrence of 1 or more
of the phenomena listed, and 8 patients received heparin
therapy in the setting of prolonged pleural effusions or
immobilization. Using standard measures and methods of
clinical follow-up, Kaulitz and colleagues3 observed throm-
bus formation and thromboembolic complications in 10
patients (7%). Eight of the patients (5.6%) presented with
systemic venous thrombus formation, and 2 patients (1.4%)
presented with stroke attributed to systemic emboli. Eight of
the 10 events occurred within the first year after surgery. It
is interesting that of the 10 patients who had complications,
8 were receiving heparin and 1 was receiving warfarin at the
time of diagnosis of the thromboembolic event. After a
detailed description of their experience, the authors closed
with the observation that in each instance, thrombus forma-
tion was associated with at least 1 potential predisposing
factor, such as prolonged immobilization, the presence of a
central venous line, protein-losing enteropathy, stenosis of
the cavopulmonary anastomosis, or atrial arrhythmia. They
concluded that their anticoagulation strategy, based on sur-
gical methods and modified in the face of purported risk
factors, was effective in the prevention of thromboembolic
complications, and they recommended against “routine”
initial anticoagulation in young children after a total cavo-
pulmonary anastomosis.
Kaulitz and colleagues3 have thus added their experience
to a steadily growing body of literature dealing with the
subject of thromboembolic events and anticoagulation ther-
apy in patients who undergo Fontan operations. The subject
was highlighted in an editorial in the March 1998 issue of
this Journal. In that very informative editorial, Monagle and
associates4 included a then contemporary review of the
literature pertaining to thromboembolism after a Fontan
procedure. It revealed no prospective studies or randomized
trials. The then-current literature included 35 publications,
of which 15 were case reports, 4 were cross-sectional point
surveys, and the remainder were retrospective series in
which thromboembolism was either the primary outcome
measure or one of multiple outcomes. The editorial con-
cluded that “current practices can only be viewed as opin-
ions based, at best, on theory and personal experiences.” It
called for well-controlled, prospective studies and sug-
gested that multicenter, randomized, controlled trials com-
paring prophylactic antiplatelet and anticoagulation thera-
pies were urgently required to provide rational scientific
guidelines for the future management of Fontan procedures
in children. In an essay titled “Thromboembolic Problems
After the Fontan Operation,” in the 2002 Pediatric Cardiac
Surgery Annual, Monagle and Karl5 updated that literature
review in an effort to represent the then contemporary body
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literature included 8 retrospective cohort studies in which
thromboembolic events were the primary outcome measure
and 13 studies in which thromboembolic events were not
the primary outcome measure, but which provided some
details regarding thromboembolic events. The number of
case reports grew steadily, and the additional cross-
sectional studies assessing thromboembolic events after
Fontan procedures brought the total number of publications
on this subject to 51. A detailed review of that literature led
the authors to the conclusion that “despite indisputable
evidence that thromboembolism following the Fontan op-
eration is an important clinical problem, there is insufficient
evidence at this time to make clear recommendations about
optimal anti-coagulant prophylaxis.” Once again, they
called for well-controlled prospective studies. The publica-
tion ended with a brief description of the protocol for a
multicenter, randomized, controlled trial comparing prophy-
lactic antiplatelet (aspirin) with anticoagulation (heparin/
warfarin) therapy, which at the time was under way in
several Australian and Canadian centers.
Earlier this year, we undertook a more contemporary
review of the literature by using the methods of Monagle
and Karl.5 Not included among the 51 reports analyzed by
Monagle and Karl in 2002 was our cohort study, also
published in 2002,6 in which low-dose aspirin prophylaxis
(81 mg/day) was used consistently and exclusively as the
prophylactic antithrombotic regimen in 72 consecutive
young children who underwent Fontan operations in a
5-year period. The patients had been monitored prospec-
tively with thromboembolism as the primary outcome mea-
sure. There were no early or late deaths. Follow-up was
complete with 2882 patient-months at a mean of 40 months.
There were no documented thromboembolic events. All
suspicious events were investigated by transesophageal
echocardiography and brain imaging. There were no hem-
orrhagic events or aspirin-related complications. This study
was unique at the time because of the consistent use of a
single antithrombotic strategy in a cohort of patients fol-
lowed up prospectively with evaluation for thromboembolic
events as a primary end point. In addition, our updated
literature search identified 21 additional studies to supple-
ment the original list of 51. These newer publications in-
cluded 8 case reports, 1 prospective cohort study that in-
cluded some details about thromboembolism among other
reported outcomes, 1 prospective cohort study (with case
controls) in which thromboembolism was the primary out-
come measure, 7 retrospective cohort studies that included
some details about thromboembolism among the reported
outcomes, and 3 retrospective cohort studies in which
thromboembolism was the primary outcome measure, in
addition to our study, which was the only one to evaluate the








Ltion. What follows is a brief outline of the findings of this
now-current review of the literature. Emphasis is placed on
some of the more recent studies.
Timing and Incidence of Thromboembolic
Complications
Monagle and Karl’s review5 included 8 retrospective stud-
ies that had thromboembolic events as the primary outcome
measure. The number of patients in these studies ranged
from 25 to 654, and totaled 1585. The percentage of patients
experiencing thromboses ranged from 3% to 16%; the per-
centage of patients experiencing stroke or arterial emboli
ranged from 3% to 19%. In a more recent report, Coon and
associates7 described the echocardiographic findings in 592
patients who underwent Fontan operations and were evalu-
ated by echocardiography between 1987 and 1999. Fifty-
two patients (8.8%) had intracardiac thrombus. Freedom
from thrombus was 92%, 90%, 84%, and 82% at 1, 3, 8, and
10 years after the Fontan operation, respectively. The ap-
pearance of thrombus was not influenced by the type of
operation or the presence of fenestrations. A cerebral vas-
cular accident was documented around the time of thrombus
detection on echocardiography in 8 of the 52 patients (15%).
Of the 52 patients with thrombus, 24 (46%) were receiving
aspirin, 6 (12%) were receiving warfarin, and 1 (2%) was
receiving heparin (for protein-losing enteropathy) at the
time of detection of the thrombus. A curve describing the
frequency of thrombus occurrence over time closely resem-
bled previously published curves for the development of
arrhythmia and protein-losing enteropathy, leading the au-
thors to suggest a lifelong risk of thrombus formation in
patients who undergo Fontan operations and the possibility
of a codependent relationship with these late complications.
Seipelt and associates8 in 2002 reported that of 85 survivors
of Fontan operations between 1986 and 1998, 13 (15.3%)
experienced thromboembolic events; 7 of 13 events oc-
curred within the first postoperative year, and a second peak
of frequency of events developed beyond 10 years of fol-
low-up. The type of operation had no influence on the rate
of thromboembolism. As in previous reports, there were
multiple instances of thrombus detected by angiography or
transesophageal echocardiography that were not clinically
suspected and that were missed by transthoracic echocardi-
ography alone. There were complex interactions between
the date of operation and prophylactic anticoagulant medi-
cal regimen. Thromboembolic events occurred in patients
with no anticoagulation, with aspirin therapy, and with
warfarin, but a lower incidence was reported in the more
recent cohort managed with warfarin. Chun and associates9
reported the incidence of stroke after Fontan procedures in
139 patients as being 3.6% (7 strokes in 5 patients). Events
occurred between 2 weeks and 9 years postoperatively. Two
strokes occurred in patients receiving aspirin and warfarin,
2 strokes occurred in patients receiving aspirin alone, and 3
The Journal of Thoracistrokes occurred in patients receiving no anticoagulant med-
ications.
An interesting cross-sectional study evaluating the prev-
alence of clinically silent pulmonary emboli in adults after
Fontan operations was reported in 2003 by Varma and
associates.10 All consecutive adult patients who underwent
Fontan operations and were attending the clinic at the Uni-
versity of Toronto Congenital Cardiac Center for Adults
underwent ventilation-perfusion scanning and blood testing
for thrombophilic tendency. Five adult patients (17%) had
an intermediate or high probability for pulmonary embolism
on ventilation-perfusion scan, all of which were confirmed
on computed tomography pulmonary angiography. No pa-
tient had a thrombophilic tendency; 30% of all patients were
taking warfarin because of atrial flutter or atrial fibrillation.
None of them had pulmonary emboli. Older age at the time
of the Fontan operation was associated with an increased
risk of silent pulmonary embolism. Three contemporary
studies11-13 document the increased sensitivity of trans-
esophageal echocardiography compared with transthoracic
echocardiography in the diagnosis of thromboembolic
events after Fontan operations. Balling and associates13
performed a cross-sectional study of 52 patients after Fon-
tan operations. Seventeen patients (33%) had thrombus seen
on transesophageal echocardiogram, only one of which was
identified on transthoracic echocardiogram. In general, the
frequency of thromboembolic events reported is increased
in recent studies compared with earlier studies, and the
significant incidence of clinically silent thromboembolic
events is noteworthy. Improved survivals, longer durations
of follow-up, improved diagnostic studies, and increased
awareness of the potential for thromboembolic events are all
features that undoubtedly contribute to the increase in the
reporting of these events.
Risk Factors for Thromboembolic Complications
The influence of patient age at operation on the risk of
thromboembolic events is unclear. In most studies, the
interactions among the date of surgery, surgical methods,
and use of anticoagulation regimens are complex. Most
studies show no correlation between the age at surgery and
the risk of thromboembolic events. Similarly, the type of
Fontan operation performed, type of material used for the
conduit or tunnel, and use of valved or nonvalved conduits
did not appear to influence the incidence of venous throm-
bosis. Potentially important exceptions to these general ob-
servations are highlighted in a report by Schoof and asso-
ciates14 of thrombus development in all 3 of their patients
who underwent extracardiac total cavopulmonary connec-
tion with bovine jugular vein as the extracardiac conduit.
Although the incidence of thromboembolic events seems to be
independent of the individual type of Fontan pathway connec-
tions, Konstantinov and associates15 described thrombosis of





Lboth intracardiac and extracardiac conduits after modified Fon-
tan operations in patients with azygos continuation of the
inferior vena cava. They infer that conduits carrying only
hepatic venous blood may have a higher likelihood of throm-
bosis. Among potential hemodynamic risk factors for throm-
boembolic events, low cardiac output, polycythemia, arrhyth-
mias, and right-to-left shunts have all been discussed more
completely than they have been analyzed or documented as
risk factors. Studies by du Plessis,16 Day,17 and their associates
examined the role of fenestration with respect to strokes. Nei-
ther study found a significantly increased incidence of stroke in
those patients with fenestrations.
Mortality Associated With Thromboembolic
Complications
The 10 patients reported to have had thromboembolic com-
plications after Fontan operations by Kaulitz and associates3
in this issue of the Journal appear to have survived after a
variety of therapeutic interventions. In general, information
on the management and outcome of thromboembolic events
in patients who underwent Fontan operations is scarce and
poorly documented. Monagle and Karl5 summarized the
management approaches described in the literature and sub-
sequent outcomes. Complete resolution of thrombosis was
achieved in 48% of cases. Death occurred in 25% of cases,
despite a variety of treatment modalities.
Hematologic Factors in Patients After Fontan
Operations
Cromme-Dijkhuis and associates18 were among the first to
measure coagulation factors in patients after Fontan opera-
tions. They described quantitative abnormalities involving
both procoagulant and anticoagulant proteins. Approxi-
mately two thirds of patients were reported to have protein
C deficiency at varying time intervals after Fontan opera-
tions. Deficiencies of other factor levels were reported, but
they have been contested because of the absence of age-
appropriate reference ranges for normal values. Jahangiri
and associates19-21 contributed several reports evaluating
coagulation factor abnormalities in patients who underwent
Fontan operations. They confirmed deficiency of certain
anticoagulant proteins such as protein C, but also described
significantly depressed levels of factor VII, a procoagulant
protein. Factor VII deficiency, if moderate in degree, should
predispose to bleeding, not coagulation. This, combined
with the fact that protein C is a natural anticoagulant syn-
thesized in the liver as a vitamin K–dependent protein,
suggests a complex interaction between procoagulant fac-
tors and anticoagulant factors in patients who undergo Fon-
tan operations. Odegard and colleagues22 at Harvard under-
took a prospective case-control study to evaluate coagulation
factor abnormalities and hemodynamic variables in pediatric
patients who underwent Fontan operations. Concentrations of
494 The Journal of Thoracic and Cardiovascular Surgery ● Marprotein C, factors II, V, VII, and X, plasminogen, and anti-
thrombin III were significantly lower in patients who under-
went Fontan operations compared with age-matched controls.
Factor VIII was significantly elevated in 6 patients (35%), 2 of
whom had protein-losing enteropathy and thromboembolic
events. A higher superior vena cava pressure was predictive of
an elevated factor VIII level (P  .003). No other significant
hemodynamic variables were predictive of a procoagulant or
anticoagulant abnormality.
Comment
Improving the outcome of Fontan operations requires a
strategy to minimize the morbidity and mortality associated
with thromboembolic complications. Despite a growing lit-
erature on the subject, there remain more controversies than
hard facts concerning the causes and nature of these com-
plications. There is general agreement that ligation of the
main pulmonary artery, leaving a blind pouch or cul-de-sac
distal to the pulmonary valve, is a worrisome substrate for
the occurrence of thromboembolism. Yet, almost every
other assertion that can be made with respect to thrombo-
embolic events after Fontan operations is the subject of
controversy. The influence of surgical factors and patient
factors is debated. There is little agreement on the efficacy
of various forms of prophylactic anticoagulant therapy. Al-
though there has been a call for prospective, multi-
institutional, randomized trials to compare anticoagulation
strategies, this is neither a simple undertaking nor one that
is guaranteed to bear fruit. A principal investigator of the
current Canadian-Australian multi-institutional study indi-
cates that difficulties with the study resulted in termination
of enrollment, although just one half of the targeted sample
size had been achieved (personal communication, Brian W.
McCrindle, September 15, 2004). One of the reasons for
premature cessation of enrollment was the high frequency
of protocol violations by participating patients and their
caregivers. At this point, the investigators of this prospec-
tive, randomized clinical trial comparing antiplatelet pro-
phylaxis (aspirin) with anticoagulation (heparin followed by
warfarin) are analyzing the data obtained during the initial
2-year period of follow-up. Rather than anticipating a de-
finitive conclusion as to the superiority of one or the other
strategy of medical therapy, they instead are hoping that the
findings of this study will ultimately lead to a more produc-
tive study design for another larger multi-institutional, ran-
domized, prospective trial.
What do we know at this point? We know that throm-
boembolic events occur more frequently after modified Fon-
tan operations than they do after any other form of cardiac
reconstruction other than prosthetic valve replacement. We
know that these events occur both early and late after
surgery. We know that these events contribute to the failure








Lfrequency in the “failing Fontan circulation.” We know that
thromboembolic events occur in patients receiving heparin,
aspirin, or warfarin, combinations of these, or none of these.
And we know, in the most general way, that the factors
predisposing to thromboembolic events after Fontan opera-
tions likely represent a complex field of biologic factors
with multiple interactions. As such, we are forced to ac-
knowledge the unlikelihood that a single agent or “single
bullet” will represent the solution to this challenging com-
plex problem. We must not be discouraged by the difficulty
of performing prospective, randomized clinical trials. In no
instance has a prized holy grail been obtained after a quick,
easy, or direct search. In the meantime, there is much to be
learned from carefully reported retrospective series such as
that by Kaulitz and associates3 in this issue of the Journal.
They report several important observations. One is the fail-
ure of heparin to prevent or treat thromboembolic compli-
cations in the setting of adverse clinical conditions such as
pathway obstruction, low cardiac output, or arrhythmias.
Another is the very low incidence of thromboembolic phe-
nomena in patients who experience a benign clinical course
and are managed with either acetylsalicylic acid or no
anticoagulant medication. Stratification of initial anticoag-
ulation therapies according to surgical methods continues to
be rather widely practiced, although reported data are at best
inconsistent. The concept of altering anticoagulation strat-
egy during the period of follow-up, according to the accrual
of certain suspected “incremental risk factors” as practiced
by Kaulitz and associates,3 seems to be worthy of consid-
eration and further investigation.
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